Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
CapsoVision, Inc.
CV
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $368.2M
$7.28
▼ -1.22%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$3.43 - $15.37
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 110.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary miniaturized camera and capsule technology with superior visualization
- AI-powered image analysis platform for enhanced diagnostic accuracy and efficiency
- Non-invasive, sedation-free alternative to traditional endoscopy procedures
- Comprehensive GI tract visualization capabilities across multiple anatomical regions
- Established clinical evidence and regulatory clearances (FDA 510(k) approvals)
Bear Case
1 risk
- Low volatility (beta -2.8).
Growth
Moderate growth ahead
Rising demand for minimally invasive diagnostic procedures and patient comfort
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-0.9% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jun 25, 2026
MAY 14, 2026
Reported EPS of -$0.15 vs -$0.13 consensus (-15.4% surprise). Revenue of $2.8M vs $3.0M expected (-6.2%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-15.4%
Next: Jun 25, 2026
Revenue trend · last 7Q
—
—
+12%
+17%
+42%
+38%
+0%
Q1 24
Q2 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.5M
$2.8M
$2.8M
$3.3M
$3.5M
$3.9M
$2.8M
Margins · last 7Q
Gross
—
Operating
—
Profit
-251.9%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Benchmark · Mar 27, 2026
vs Industry
How CV stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related